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Crystal Structure of Recombinant
Human Interleukin-22
in human cells [2]. In vitro experiments showed that IL-
22 expression is induced by interleukin-9 (IL-9) in T cells
and mast cells [1]. IL-9 induction is rapid (within 1 hr)
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Human and mouse IL-22 (hIL-22 and mIL-22) haveCEP 13560-970
179 residues, including four cysteines, and share 79%Sa˜o Carlos, Sa˜o Paulo
amino acid sequence identity. On the other hand, theBrazil
hIL-22 (mIL-22) sequence has only 25% (22%) identity
with human IL-10 (hIL-10). Most of the conserved resi-
dues between IL-22 and IL-10 are located in the C-ter-Summary
minal half of the protein, which has been found to be
critical for IL-10 activity, leading to the hypothesis thatInterleukin-22 (IL-10-related T cell-derived inducible
IL-22 and IL-10 may share common or related biologicalfactor/IL-TIF/IL-22) is a novel cytokine belonging to
activities. The only three-dimensional structures ofthe IL-10 family. Recombinant human IL-22 (hIL-22)
members of the IL-10 family of cytokines known at pres-was found to activate the signal transducers and acti-
ent are those of IL-10 [11, 12, 13] and its viral homologvators of transcription factors 1 and 3 as well as acute
from Epstein-Barr virus (EBV) [14].phase reactants in several hepatoma cell lines, sug-
The fact that mIL-22 is induced in various organs bygesting its involvement in the inflammatory response.
lipopolysaccharide (LPS) suggests that the role of thisThe crystallographic structure of recombinant hIL-22
new cytokine is not restricted to the immune systemhas been solved at 2.0 A˚ resolution using the SIRAS
[2]. It was also found that hIL-22 activates the signalmethod. Contrary to IL-10, the hIL-22 dimer does not
transducers and activators of transcription factors 1 andpresent an interpenetration of the secondary-struc-
3 in several hepatoma cell lines. IL-22 stimulation ofture elements belonging to the two distinct polypep-
HepG2 human hepatoma cells upregulated the produc-tide chains but results from interface interactions be-
tion of acute phase reactants, such as serum amyloidtween monomers. Structural differences between
A, 1-antichymotrypsin, and haptoglobin [2]. A similarthese two cytokines, revealed by the crystallographic
acute phase reactant induction was also observed instudies, clearly indicate that, while a homodimer of
mouse liver upon IL-22 injection, suggesting involve-IL-10 is required for signaling, hIL-22 most probably
ment of IL-22 in the inflammatory response. In addition,interacts with its receptor as a monomer.
IL-22 might play a role in allergy and asthma due to the
involvement of IL-9 in these two pathologies [15, 16].Introduction
Furthermore, the IL-22 gene is located on human chro-
mosome 12q [17], where several loci potentially linkedInterleukin-22 (IL-22) is a novel protein that was recently
identified in murine cells [1] and was subsequently found to asthma have been identified by genetic studies [18].
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Cytokines exert their actions by binding to specific cell inferred amino acid sequence derived from the cDNA [2]
was used in the final model side chain assignment.surface receptors, leading to the activation of cytokine-
specific signal transduction pathways. Recent results
[3, 4] show that the functional IL-22 receptor complex Quality of the Model
consists of two receptor chains, the CRF2-9 (IL-22R) The initial structure of hIL-22 was improved by a number
chain and the CRF2-4 (IL-10R2 or IL-10R) chain. The of cycles of refinement and rebuilding using the CNS
latter has been demonstrated to be a functional compo- package [27]. The final model is characterized by an R
nent of the IL-10 signaling complex [19]. This is the first factor of 0.188 and an Rfree of 0.22 for the Nat-hIL-22example within the class II cytokine receptor family of data in the resolution range from 21.7 to 2.0 A˚.
a receptor being utilized as a component of multiple The isolated cDNA of hIL-22 encodes a protein of
distinct cytokine signaling complexes. A similar sharing 179 amino acids, the first 33 of which are predicted to
is also observed in IL-2, IL-4, IL-7, IL-9, and IL-15 recep- function as a signal sequence [3]. The N-terminal amino
tor complexes ( common chain, c). acid analysis of hIL-22 confirms that the mature protein
Here we describe the structure of recombinant hIL- begins at amino acid residue 34. The refined model of
22 refined to 2.0 A˚ resolution and its comparison with hIL-22, a dimer in the asymmetric unit (Figure 1), in-
the crystallographic models of hIL-10 [11, 12, 13] and cludes monomer A, with 142 amino acid residues
hIFN- [20]. The possible receptor binding sites were (Ser38–Ile179), monomer B, with 141 amino acid resi-
inferred on the basis of structural comparison with the dues (His39–Ile179), and 189 water molecules. A total
hIFN-/hIFN-R complex [20], the recently determined of 93.8% and 6.2% of the amino acid residues adopt a
complex of IL-10 with its receptor IL-10R1 [21], and conformation corresponding to the most favored and
amino acid sequence alignments. Structural compari- additionally allowed regions of the Ramachandran plot,
sons with IL-10 and IFN- receptor complexes clearly respectively (see Table 2 for further information about
indicate that, while a homodimer of IL-10 and/or IFN- refinement and geometry statistics). No residues have
is required for signaling, hIL-22 most probably interacts been encountered in the disallowed regions of the Ra-
with its receptor as a monomer. machandran plot. Pro113 is in the cis conformation.
Alternative conformations of the side chains were found
for residues Met172 (monomer A) and Asp43, Ser45,Results and Discussion
Arg55, Ile75, His81, Arg124, Ile161, and Leu174 (mono-
mer B). The electron density for part of loop DE (residuesStructure Determination
127–132) is weak, resulting in high temperature factorsPurified recombinant hIL-22 was crystallized at the Pro-
for this part of the protein (Figure 2).tein Crystallography Laboratory of the Brazilian National
Each monomer of the hIL-22 model, as shown in Fig-Synchrotron Light Laboratory (LNLS) using the hanging
ure 1B, is characterized by six  helices (A–F) that folddrop method. Several attempts to improve crystal qual-
in a compact bundle. Helix A (amino acid residuesity were performed, including pH and precipitant con-
Lys44–Ser64) is linked to a short helix, B (Glu77–Phe80),centration refinement, detergent addition, and mac-
by a large loop, AB (Leu65–Gly76). Helix A has a kinkroseeding. Well-diffracting crystals were obtained using
at Gln48–Gln49, presumably due to a hydrogen bondsodium tartrate and TRITON X-100 detergent in HEPES
between N-Gln49 and O-Ser45 (2.79 A˚ and 2.55 A˚ inbuffer at pH 7.5. The crystal space group was deter-
monomers A and B, respectively). This divides helix Amined to be P212121 (see Experimental Procedures for into two unequal parts: A1 and A2. Loop BC (His81–Glu87)details).
connects helix B to helix C (Arg88–Glu102). Helix C isThe structure of hIL-22 was solved by X-ray diffraction
joined to helix F by a disulfide bond between Cys89 andusing the SIRAS method. The data sets of an iodine
Cys178. Another loop (CD; Val103–Tyr114) links helix Cderivative (I-hIL-22) and a native crystal (Nat-hIL-22)
to helix D (Met115–Leu129). According to PROCHECKwere collected at the Protein Crystallography beamline
[28], a small difference in secondary structure between[22, 23] at the LNLS (Campinas, Sa˜o Paulo, Brazil). The
monomers is observed at the loop CD region. A smallI-hIL-22 derivative was prepared according to the quick-
 helix is observed between amino acid residues Phe105cryosoaking procedure [24, 25] for fast derivatization of
and Gln107 of monomer B. Helix D is connected to helixprotein crystals. One additional Hg derivative data set
E by a disordered loop (DE; Ser130–Asp138). This loopwas collected at the X4A beamline at NSLS (Upton, New
is stabilized, at least in the vicinity of Cys132, by anotherYork). These data did not provide a strong isomorphous
disulfide bond between Cys132 and Cys40, the latter inor anomalous signal and were therefore used only at the
the N-terminal coil. Finally, a simple junction EF (Gly156)later stages of refinement and during the construction of
joins the last two helices, E (Leu139–Leu155) and Fdisordered loops, as a quasi-native data set. Details of
(Glu157–Cys178). Probably, as a consequence of a di-the preparation of native and derivative crystals for data
sulfide bond between Cys89 and Cys178, the latter be-collection as well as data statistics are given in Table 1.
longing to the C-terminal of helix F, a kink at Glu166SIRAS-derived phases using native and iodine deriva-
divides helix F into two parts: F1 and F2.tive data have a mean figure of merit of 0.45 in the
resolution range from 21.7 to 2.4 A˚. Due to the high
resolution and completeness of the I-hIL-22 data set Dimer Formation
A significant part (61%) of the volume of the asymmetricand the quality of the solvent-flattened electron density
map, automatic construction of an hIL-22 hybrid model unit (6.27  104 A˚3 ) is occupied by a dimer of hIL-22. A
small fraction of this volume (8%) is filled with orderedcould be performed by the ARP/wARP program [26]. The
Recombinant Human Interleukin-22 Crystal Structure
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Table 1. Details of the Preparations and Data Collection Statistics of hIL-22 Crystals
Nat-hIL-22 I-hIL-22 Hg-hIL-22 (Quasi-Native)
Wavelength (A˚) 1.54 1.54 1.54
Space group P212121 P212121 P212121
Unit cell parameters (A˚) a  55.43, b  61.61, a  56.05, b  61.78, a  56.04, b  61.71,
and c  73.47 and c  73.63 and c  74.61
Resolution (A˚) 21.7–2.00 (2.05–2.00) 21.8–1.92 (1.96–1.92) 22.4–1.90 (1.97–1.90)
Number of reflections 61,846 182,876 55,855
Number of unique reflectionsa 16,382 37,777 29,854
I/(I)	 14.5 (3.8) 13.4 (3.1) 8.2 (2.1)
Multiplicity 3.8 (3.4) 4.8 (4.3) 1.9 (1.7)
Completeness 92.7 (82.3) 99.9 (99.7) 75.9 (77.9)
Rmergeb 8.2 (35.0) 11.7 (43.9) 10.0 (49.9)
Data collected (degrees) 103 248 70
Cryoprotectant solution mother liquor mother liquor mother liquor
15% ethylene glycol 15% ethylene glycol 15% ethylene glycol
0.125 M Nal 5 mM HgCI2
Soaking time 30 s 180 s 10 hr
Statistical values for the highest resolution shells are shown in parentheses.
a Multiplicity of derivative (native) data sets calculated with Friedel-related reflections treated separately (as equivalent).
b Rmerge  
hkl|Ihkl  Ihkl	|/
hkl Ihkl.
water molecules. The monomers are essentially equal; The second conformational difference, around residue
Asn69, is a consequence of a crystallographic contacthowever, a number of significant differences in the main
chain conformation in the vicinity of amino acid residues between side chain atoms of Asn69 and Thr70 of mono-
mers A and B, respectively. Gly136 is localized in disor-Gln48, Asn69, Gly136, and Lys154 are observed (Figure
2). These differences could mostly be explained by crys- dered loop DE. This fact explains the rmsd (root mean
square deviation) of around 2.0 A˚ in the vicinity of thistallographic and noncrystallographic contacts. The rea-
son for a significant positional difference between residue. Finally, the last major difference between mono-
mers is found close to Lys154. In this region three dis-monomers around Gln48 is the fact that this region in
monomer A is involved in interface interactions, while tinct interactions of Lys153 and Lys154 from monomer
B (O1-Glu102/N-Lys153 at a distance of 2.68 A˚, O1-the same region in monomer B is exposed to the solvent.
Besides this, the presence of two intramolecular interac- Asn46/N-Lys153 at 2.78 A˚, and O1-Glu160/N-Lys154
at 2.80 A˚), which are absent in monomer A, are responsi-tions (O1-Asp43/O-Ser45 at a distance of 2.64 A˚ in
monomer A and O-Asn46/N2-Gln49 at 2.55 A˚ in mono- ble for a high rmsd of main chain atoms.
Unlike hIL-10, the hIL-22 dimer does not result frommer B) contributes to a relative change in main chain
atomic positions between residues Leu42 and Pro50. the intertwining of the main chain of each monomer
Figure 1. Structure of the IL-22 Dimer
(A) Stereo view of the C trace of the dimeric
structure of hIL-22.
(B) Schematic representation of the second-
ary structure of the hIL-22 dimer, according
to PROCHECK [28], showing the location of
the two disulfide bonds (Cys40-Cys132 and
Cys89-Cys178) represented by ball and stick
diagrams. The figures were prepared using
Molscript [29], Bobscript [30], and Ras-
ter3D [31].
Structure
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Table 3. Intermolecular ContactsTable 2. Refinement Statistics and Quality of the hIL-22 Model
Monomer A Monomer BRefinement Statistics
Resolution range (A˚) 21.7–2.0 Residue Atom Residue Atom Distance (A˚)
Total number of reflections 15,684
Arg175 N2 Glu166 O1 2.57Working set number of reflections 14,892
Phe57 O Asn176 N2 2.64R factor (%) 18.8
Arg73 N2 Val83 O 2.71Test set number of reflections 792
Lys44 N Ser64 O 2.85Rfree (%) 22.0
Arg175 N1 Asp168 O2 2.86Total number of protein atoms 2330
Asn176 N2 Ile75 O 2.91Total number of water molecules 189
Gln48 O Lys61 C 2.96
Stereochemical Parameters Lys44 N Glu166 O1 2.98
Lys61 N Ile179 OT1 3.12Rmsd bond distances (A˚) 0.006
Gln49 O1 Lys61 N 3.15Rmsd bond angles () 1.1
Average B factors The distance cutoff of 3.2 A˚ was used.
Residue atoms (A˚2) (A, B) 24.3 (22.3, 26.2)
Main chain atoms (A˚2) (A, B) 22.1 (20.2, 24.1)
Side chain atoms (A˚2) (A, B) 26.3 (24.4, 28.1)
Water molecules (A˚2) 37.3 Thr53–Arg88 and Glu166–Ile179 in monomer B, has a
Average B factor rmsd significant number of hydrophobic residues. Intermolec-
Residue atoms (A˚2) (A, B) 2.5 (2.6, 2.5)
ular interface contacts closer than 3.2 A˚ are listed inMain chain atoms (A˚2) (A, B) 1.0 (1.0, 1.0)
Table 3. The electrostatic and hydrophobic distributionSide chain atoms (A˚2) (A, B) 1.9 (2.0, 1.8)
of the hIL-22 surface, together with the position of theWater molecules (A˚2) 11.4
principal amino acid residues involved in the formationNoncrystallographic Symmetrya
of the dimer, are given in Figure 3.
Rmsd coordinates
C atoms (A˚) 0.911 Potential Glycosylation Sites
Main chain atoms (A˚) 0.884
According to the predicted primary structure, human IL-All bonded atoms (A˚) 1.670
22 has three potential glycosylation sites (Asn-Xaa-Thr/Rmsd B factors
C atoms (A˚2) 10.04 Ser) localized in helix A (Asn54-Arg55-Thr56), loop AB
Main chain atoms (A˚2) 10.05 (Asn68-Asn69-Thr70), and helix C (Asn97-Phe98-Thr99).
All bonded atoms (A˚) 10.77 Since the recombinant hIL-22 used in crystallization is
not glycosylated, we attempted an analysis of the possi-a Between subunits A and B.
ble interactions between oligosaccharides and hIL-22
by calculating the accessible area of each residue in all
three putative glycosylation sites. The results demon-(Figure 1). An interface area of approximately 2250 A˚2,
strate that site 2, localized in loop AB, has a largerwhich corresponds to 30% of the total surface area of a
accessible area in both the IL-22 dimer and monomer.monomer, is involved in the dimer formation. The buried
A solvent-accessible area of approximately 37 A˚2 wassurface for the chosen dimer conformation is at least
found for the N2 atom of Asn68 and for the O1 atomtwice that of any other possible dimer generated as a
of Thr70, indicating that there is no steric hindrance toresult of crystal packing (960 A˚2 or less). Besides this,
their participation in N-glycosyl and O-glycosyl links,the dimer interface, which is formed mostly by residues
respectively. On the other hand, sites 1 and 3 seemArg41–Phe80 and Asp168–Ile179 in monomer A and
to be able to participate only in N-glycosyl links. The
accessible areas of O1-Thr56 and O1-Thr99 are 0 and
6 A˚2, respectively, both in the monomer and dimer of
IL-22, whereas the N2-Asn54 and N2-Asn97 atoms
possess, respectively, surface-accessible areas of 24
and 18 A˚2. This structural analysis is in agreement with
biochemical studies suggesting that these three sites
are of the N-glycosyl type [4]. The present structure
shows that putative glycosylation sites 1 and 2 reside
close to the dimer interface, and glycosyl linkages at
these positions might hamper dimer formation. It is diffi-
cult to conclude whether glycosylation of the protein
will interfere with its interactions with receptor chains
(see Potential Receptor Binding Sites below) on the ba-
sis of the current analysis alone. Further biochemical
studies are required to address this question.
Figure 2. Least-Square Fit of Monomer A to Monomer B and Tem-
Comparison with IL-10 and IFN-perature Factors Plots
The crystallographic structure of hIL-22, as seen in Fig-The root mean square deviation (rmsd) and B factors are shown as
ure 1B, is a compact dimer with a buried surface areaa function of residue number. Only main chain atoms were used in
the calculation. of approximately 2250 A˚2. Several intermolecular inter-
Recombinant Human Interleukin-22 Crystal Structure
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Figure 3. The Contact Surface of the hIL-22
Dimer
The figure is colored according to residue
hydrophobicity (A and B) and electrostatic
potential (C and D). Interface views of mono-
mer A (A and C) and monomer B (B and D)
are shown. In parts (A) and (B), the darker
the yellow, the greater the hydrophobicity. In
parts (C) and (D), areas of negative, positive,
and neutral electrostatic potential are de-
picted in red, blue, and white, respectively.
The figures were prepared with GRASP [32].
actions along the interface surface keep the monomers and F. This leads to the intertwined dimer formation
[11, 12, 13]. A monomeric form of hIL-10 could only betogether. Each monomer, composed of a single domain,
is formed by six  helices (A–F) from the same polypep- formed if the Cys80-Cys132 disulfide bond were to be
reduced or if a small insertion were made after Cys132tide chain. In contrast, the crystallographic structures
of hIL-10 [11, 12, 13] and hIFN- [20, 33] revealed the [11]. The latter approach has been applied with success
to hIL-10, where the insertion of a small polypeptidepresence of a homodimer composed of two -helical
domains formed by the intertwining of  helices donated linker in the loop connecting the swapped secondary
structure elements led to the formation of a monomericby the first and the second monomer composing a di-
mer. The first four helices of one chain (A–D) together protein [34]. Similarly to IL-10, the hIFN- intertwined
dimer is formed because loop DE is not long enough towith helices E and F from the second chain form the
first domain, while helices A–D, E, and F form the sec- allow the folding of helices E and F into the same domain.
In hIL-22 just one disulfide bond (Cys40-Cys132) ex-ond domain.
There are, however, significant structural similarities ists within loop DE. This renders sufficient flexibility and
extension of the loop to bring helices E and F into abetween IL-22, IL-10, and INF- (Figure 4). In all these
proteins, helices A–D of each monomer form a rigid close interaction with helices A–D and to complete the
folding of the monomer. A second disulfide bondframework with a highly hydrophobic depression in its
middle. This depression is covered in hIL-22 by helices (Cys89-Cys178), in the C-terminal of helix F, adds to the
rigidity of the final hIL-22 structure.E and F from the same monomer, while, in hIL-10 and
hIFN-, this is accomplished by helices E and F (from The best superposition of hIL-22 onto hIL-10 and
hIFN-, respectively, was obtained using a single do-the second monomer). The basic reason for these differ-
ences is in loop DE. There are two cysteine residues, main of the hIL-10 and hIFN- dimers and a monomer
of hIL-22 (Figures 4A and 4C). The superposition of hIL-Cys126 and Cys132, in the hIL-10 DE loop that make
two distinct disulfide bonds with residues Cys30 and 10 and hIFN- onto hIL-22 yielded an rmsd of 1.9 A˚
and 2.3 A˚ for 432 and 300 pairs of main chain atoms,Cys80, respectively. (Here we adopt the residue num-
bering according to the hIL-10 cDNA sequence). These respectively. Helices A–D of the hIL-22 monomer super-
impose with helices A–D of one of the monomers of hIL-two disulphide bridges restrict the flexibility of the poli-
peptide chain and the length of loop DE in such a manner 10 and hIFN-. Helices E and F fit nicely into the spatial
position occupied by helices E and F of the secondthat helices E and F cannot fold onto their respective
monomer to occupy position of their counterparts, E monomer. The 3D superposition of the structures al-
Structure
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Figure 4. Structural Comparison of hIL-22, hIL-10, and hINF-
Ribbon diagram showing the superposition of the hIL-22 monomer (green) onto (A) a single hIL-10 domain (helices A–D, light blue; helices
E–F, yellow; helices A–D, E, and F were omitted) and (C) a single hIFN- domain (helices A–D, dark blue; helices E–F, orange; helices
A–D, E, and F were omitted). Superposition of the hIL-22 dimer (individual monomers colored in red and green) onto (B) the hIL-10 dimer
(light blue and yellow) and (D) the hIFN- dimer (dark blue and orange).
lowed us to perform the structure-based sequence is common to IL-22 and IL-10 and is necessary for signal-
ing, whereas the first one is specific for IL-22 [3, 4] andalignment for hIL-22, hIL-10, and hIFN- shown in Figure
5. Inspection of the hIL-22 and hIL-10 structure superpo- shows some primary sequence homology with another
receptor chain of IL-10 (the IL-10R1). The binding affinitysition revealed strong similarities in the conformation of
the main chain trace of helices E (E) and F (F) and, to of IL-22 and IL-10 to CRF2-4 seems different. CRF2-4
alone is sufficient to bind IL-22, while the presence ofa lesser extent, several parts of loop AB, helix C, and
helix D. As can be seen in the sequence alignment, a second receptor chain is required for efficient IL-10
binding. Moreover, CRF2-9 and CRF2-4 present signifi-all these regions have high sequence similarity. Some
significant differences in the regions of the N-terminal cant sequence homology to the INF- receptor, INF-
R. The three-dimensional structure of hINF-R hascoil, helix A, helix B, loop BC, loop CD, and, clearly,
loop DE were also observed. been solved as a complex with its ligand [20]. The struc-
ture of hIL-22 was superimposed onto the structure ofReasonable superposition of hIL-10 or hIFN- dimers
onto the hIL-22 dimer has proven to be impossible. The hINF-/hINF-R complex in order to identify the resi-
dues putatively involved in the hIL-22/receptor interac-dimer formation in each case is so different that only
one monomer of hIL-22 could be superimposed with tions. A similar structural comparison using the hGH/
hGHBP complex had been used previously in the puta-one domain from hIL-10 or hIFN-, while the second
domain of these structures occupies a completely differ- tive receptor binding sites analysis of IL-10 [11].
The superposition of hIL-22 onto the hINF-/hINF-Rent spatial position (Figures 4B and 4D). In hIL-10 and
hIFN- the intertwining of  helices is essential for the complex indicates that one possible receptor binding
site is localized in the region formed by helix A, loopformation and integrity of the molecules, which assume
the form of V-shaped dimers, while dimer formation is AB, and helix F of hIL-22 (region 1, R1; see Figures 4D,
6A, and 6B). Among the 17 residues involved in hINF-/not required for folding in hIL-22. It must be stressed
that the buried surface on the hIL-22 interface coincides hINF-R interactions (closer than 3.4 A˚), only 2 residues
do not have their hIL-22 structural counterparts local-with the part of the external surface of the hIL-10 and
hIFN- V-shaped dimer surfaces (Figures 4B and 4D). ized in R1. Nine of the 17 residues localized in R1 are
not sufficiently close to their hINF- counterparts, which
may explain the inability of hIL-22 to bind to hINF-R.Potential Receptor Binding Sites
The major differences between hINF- and hIL-22 withinTwo receptor chains have been identified for IL-22,
namely, CRF2-9 and CRF2-4. The second receptor chain R1 are observed in loop AB. Distances of more than
Recombinant Human Interleukin-22 Crystal Structure
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Figure 5. Primary Structure Alignment of Murine IL-22, Human IL-22, Human IL-10, and Human IFN-
Whenever possible the three-dimensional information was used to improve the alignment. Disulfide bonds in hIL-22 are marked with green
circles. The amino acid similarity between hIL-22, hIL-10, and hIFN-, as calculated by the program ALSCRIPT [35], is shown in three different
shades of blue. The darker color corresponds to higher sequence similarity. Residues conserved in mIL-22 and hIL-22, yellow; human IL-22
secondary structure elements, red. The figure was drawn using the program ALSCRIPT.
7 A˚ are found between their main chains. However, six network with Asp162, Gln56, and the main chain car-
bonyl oxygen of Ser159 from IL-10 [21]. Remarkably,relatively conserved residues (Lys61, Thr70, Asp71,
Lys162, Glu166, and Leu169) occupy almost the same sequence alignment shows that the CRF2-9 receptor
chain contains an arginine residue homologous to Arg96spatial position as six hINF- residues (Lys35, Asp47,
Asn48, Lys131, Glu135, and Gln138; cDNA numbering), of IL-10R1. One may infer, therefore, that Arg 175 of IL-
22 monomer A binds to residues Glu166 and Asp168 ofas can be seen in Figure 6A.
A comparison with the hIL-10 putative receptor bind- IL-22 monomer B in a way that resembles CRF2-9 bind-
ing to this cytokine (Figure 6C).ing site [11] shows that the same region 1 (helix A, loop
AB, and helix F in the case of hIL-10) should be involved Amino acid residues Pro38, Arg42, Arg45, and Glu169
form the 1b subsite in the IL-10/IL-10R1 structure. Thesein receptor interactions. Amino acid residues Gln60,
Asp62, Asn63, Lys156, Glu160, Asp162, Asn166, and residues are equivalent to Gln48, Ile52, Arg55, and
Arg175 of the IL-22 molecule. Gln48 and Arg175 of IL-Glu169 of the hIL-10 binding site have their hIL-22 coun-
terparts in residues Asn68, Thr70, Asp71, Lys162, 22 monomer A again form part of the dimer interface
interacting with the residues Lys61, Glu166, and Glu168Glu166, Asp168, Met172, and Arg175. Among these
eight residues, four of them (Thr70, Asp71, Lys162, and of monomer B (Table 3). This means that a large part of
the IL-22 homodimer interface is formed by interactionsGlu166) were also found in the hIL-22:INF-/INF-R
structure comparison. of the amino acid residues potentially involved in recep-
tor binding.After the current structure was determined and its
structural comparison with the hINF-/hINF-R and The structural comparison of hIL-22 with the hINF-
/hINF-R and IL-10/IL-10R1 complexes leaves littlehGH/hGHBP complexes had been performed, the crys-
tallographic structure of the IL-10/IL-10R1 became doubt that region 1 is a putative receptor binding site.
The three-dimensional and amino acid sequence simi-available [21]. The structure of this complex confirms
that the prime binding site of the IL-10 with its high- larities observed between hIL-22, hIL-10, and INF-, re-
spectively, in region 1, especially between helices F andaffinity receptor (site 1a) includes residues Gln56, Gln60,
Asp62, Asn63, Lys156, Ser159, Glu160, and Asp162, F, indicate that this region might serve as the high-
affinity receptor binding site. Further support for thiscorresponding to amino acid residues Ser64, Asn68,
Thr70, Asp71, Lys162, Gly165, Glu166, and Asp168 in hypothesis comes from the similarities in amino acid
sequence of IL-10R1, CRF2-9, and INF-R, particularlyhIL-22. Of these, three amino acid residues, Ser64,
Glu166, and Asp168, are involved in intermolecular con- in the loop regions involved in the interactions with the
respective cytokines [21]. However, the differences ob-tacts at the homodimer interface of the current IL-22
structure (Table 3). Besides this, Asp168 and Glu166 of served in loop AB, including the presence of a potential
glycosylation site in hIL-22 and, also, the lack of suffi-monomer B form salt bridges with Arg175 of the neigh-
boring monomer, A. Arg175, therefore, occupies a posi- cient biochemical data, do not allow us to definitively
infer which receptor chain binds region 1 of hIL-22. Intion equivalent to that of Arg96 of the IL-10R1 receptor
in the IL-10/IL-10R1 complex. Arg96 is one of the most fact, considering the hypothesis that the glycosylation
site in the hIL-22 AB loop may affect receptor recogni-important residues involved in the IL-10/Il-10R1 com-
plex formation, as it forms an extensive hydrogen bond tion and also that IL-10R1 and INF-R have low, but
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Figure 6. Molecular Details of the Putative Receptor Binding Site (R1) of IL-22
(A) Superposition of the hIFN-/hIFN-R complex. hIFN-, dark blue and orange; hIL-22 monomer, green. Amino acid residues forming the
putative receptor binding site of IL-22 and the binding site of hIFN- to the hIFN-R receptor are represented by ball and stick diagrams,
colored according to the molecule coloring scheme and labeled.
(B) Ribbon diagram of hIFN- bound to the hIFN-R receptor. hIFN-, dark blue and orange; hIFN-R, cyan. The hIL-22 monomer (green)
is superimposed with one of the hIFN- domains.
(C) Superposition of hIL-22 onto hIL-10. Only residues Glu160 and Asp162 of the hIL-10 receptor binding site 1a and residue Arg96 of hIL-
10R1 are shown superimposed onto the hIL-22 putative binding site residues Glu166 and Asp168 of monomer B and amino acid residue
Arg175 of monomer A. Note that the amino acid residue Arg175 at the hIL-22 homodimer interface in the hIL-22 dimer structure mimics hIL-
10R1 Arg96 interactions with the correspondent residues of the hIL-10 1a binding site in the hIL-10/Il-10R1 complex [21]. hIL-10, gold; hIL-
22 monomer A, red; hIL-22 monomer B, green; IL-10R1 residue Arg96, gray. Numbers in black show distances in A˚.
(D) A ribbon diagram of hIL-10 bound to the hIL-10R1 receptor. hIL-10, light blue and gold; hIL-10R1, gray; hIL-22 monomer, superimposed
with one of the hIL-10 domains, green.
detectable, similarity to CRF2-4, one may suggest that filtration column was 1 mg/ml, and the eluted recombi-
nant IL-22 sample had an apparent molecular weight ofR1 could also be the recognition/binding site for CRF2-4.
This hypothesis also finds support in the model for the 15 kDa and was fully active.
DLS measurements performed at a protein concentra-IL-10/IL-10R1/CRF2-4 complex, where both receptors
share the same binding site [21]. tion of 5 mg/ml resulted in an apparent Stokes radius
of 2.08  0.06 nm, which corresponds to a standardIn the present crystallographic model, region 1 of each
monomer is hidden at the dimer interface. Moreover, a molecular weight of approximately 19 kDa. This demon-
strates that hIL-22 was present in solution predomi-number of potential receptor binding residues are di-
rectly involved in the dimer formation (see Table 3). nantly in a monomeric form, in line with the results of
the gel filtration studies. An excellent correlation withTherefore, an hIL-22 receptor chain could only bind a
monomer of hIL-22, which would require dissociation the Stokes radius of 2.11 nm calculated using the HY-
DROPRO program [36] on the basis of the crystal struc-of the dimer observed in the present crystallographic
structure. In contrast, the hIL-10 and hIFN- dimers do ture of the monomer determined in the present work
further confirms this conclusion. Therefore, both gel fil-not require dissociation in order to interact with their
receptor, since their high affinity receptor binding sites tration and DLS studies demonstrate that hIL-22 is a
monomer at physiologically relevant concentrations (5are located on the external part of the V-shaped dimer
surface. mg/ml).
The DLS measurements performed on the proteinTo further assess the oligomerization state of hIL-22
in solution, gel filtration and dynamic light-scattering sample concentrated to 10 mg/ml resulted in a Stokes
radius of 2.74  0.06 nm and an apparent molecular(DLS) studies were undertaken. The state of oligomeriza-
tion of the protein was found to be concentration depen- weight of 35.5 kDa, suggesting that a dimer is the pre-
dominant oligomeric form under these conditions. Thedent. The initial protein concentration applied to the gel
Recombinant Human Interleukin-22 Crystal Structure
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apparent Stokes radius of 2.58 nm computed by HY- interpenetrating polypeptide chains, the hIL-22 dimer is
comprised of two independent monomers held togetherDROPRO from the crystallographic model of the dimer
occupying the asymmetric unit is in agreement with the by intermolecular interactions. No intertwining of  heli-
ces was observed in the crystallographic structure ofexperimental results. This indicates not only that, under
conditions of crystallization, hIL-22 predominantly forms hIL-22.
The superposition of hIL-22 onto the hIFN-/hIFN-Rdimers in solution, but also that the calculated hydrody-
namic parameters of the dimers observed in the crystal and hIL-10/hIL-10R1 complexes allowed us to identify
a possible hIL-22 receptor binding site (region 1, R1).are close to the experimentally determined hydrody-
namic parameters of the dimers observed in solution. This site is comprised of helix A, loop AB, and helix F,
similarly to the first binding site reported for hIL-10 [11,Assuming that the CRF2-4 and CRF2-9 receptor
chains have separate binding sites, there should be at 21]. The overall similarity of hIL-22 to hIL-10, especially
in the region of this putative receptor binding site and,least two distinct sites for receptor binding to the IL-22
molecule. A second possible binding site in hIL-22 could also, in their respective high-affinity receptors (CRF2-9
and IL-10R1), indicates that this site could represent thenot be easily identified from inspection of the interac-
tions between hINF- and hINF-R or hIL-10 and hIL- binding site for CRF2-9. However, the lack of biological
studies does not allow us to unambiguously conclude10R1. Nevertheless, the C-terminal parts of helices C
and E of each hIL-22 monomer could be another poten- whether this is a binding site for the CRF2-9 or CRF2-4
receptor chains or the common binding site for both oftial binding site (region 2, R2) for the common receptor
chain (CRF2-4). A sequence comparison between hIL- these receptors [21]. Remarkably, the receptor binding
site in R1 is occluded in the hIL-22 structure as a conse-22 and several IL-10s shows that several amino acids
are conserved within R2 (sequences FTLEEVL and KLGE quence of dimer formation. This leads us to propose
that the active species of hIL-22 is a monomer. This isin hIL-22 helices C and E, respectively). These regions
(R2) are localized at the surface of the IL-22 opposite in a perfect agreement with the results of gel filtration
and DLS studies demonstrating that hIL-22 is a mono-from R1. Localization of each putative binding region
(R1 and R2) on the opposite sides of the hIL-22 molecule mer at physiologically relevant concentrations. Several
other cytokines have already been shown to dimerizewould allow for interaction with two receptor chains
simultaneously. The hIL-10 R2 counterparts are local- at high concentrations while being biologically active
as monomers (see, for example, [38] and [39] and theized at the inner part of the V-shaped dimer surface.
The angle between each hIL-10 domain in the V-shaped references therein). An observation that an engineered
human IL-10 monomer is biologically active in cellulardimer could be large enough to allow for the interaction
of two CRF2-4 receptor chains with the two putative proliferation assays further corroborates this hypothe-
sis [34].binding sites at R2 (Figure 4B).
Another putative binding region (region 2, R2) for
CRF2-4 (or IL-10R2) was identified on hIL-22 by surface-
Biological Implications mapped sequence comparison with hIL-10. R2 is local-
ized on the opposite side from the first binding site
Cytokines are proteins that exert their action by binding (region 1, R1), leaving enough room for binding for a
to specific cell surface receptors, leading to the activa- second receptor. Primary structure comparison of sev-
tion of cytokine-specific signal transduction pathways. eral IL-10s and IL-22s from different organisms indicates
These proteins play several important biological roles, that the residues forming the second putative binding
including multiple and generally immunosuppressive site are highly conserved.
activities, immunomodulatory and antiviral effects, and The structure of hIL-22 presented here brings us
stimulation of T cell growth, among others [37]. IL-22 is closer to an understanding of its interactions with its
a new cytokine expressed in T cells upon activation by receptor chains and the mechanism of signal transduc-
IL-9 and in mast cell, thymus, and brain upon activation tion exerted by this molecule. Moreover, this structural
by concanavalin A (ConA), indicating that this factor information may help in the solution of the structure of
might exhibit pleiotropic activities, within and outside the IL-22:receptor complex and also offers the possibil-
of the immune system [1]. Two different receptor chains, ity of structure-based site-directed-mutagenesis map-
CRF2-9 and CRF2-4, have been identified as compo- ping of the receptor binding sites.
nents of the IL-22 signaling complex [3, 4]. A role for this
protein in inflammatory processes has been suggested Experimental Procedures
after observing that IL-22 induces STAT activation and
Protein Expression and Purificationupregulates acute phase reactant production by liver
Recombinant human IL-22 was produced in E. coli as follows. Thecells [2].
IL-22 sequence (corresponding to amino acids Q29–I179) was ampli-
Here we report the first crystallographic structure of fied by PCR from a cDNA clone using primers hTIFa (5-GGCCCTC
this new cytokine, human IL-22. Possible receptor bind- TTGGTACATATGCAGGGAGGAGCAGCTGCG-3) and hTIFb (5-CAG
CTTTGCTCTGGGGATCCTTATCAAATGCAGGCATTTCTCAG-3). Theing sites were identified via comparison with the related
PCR product was digested with NdeI and BamHI and cloned intocomplex structures of hIFN-/hIFN-R and hIL-10/hIL-
the pET3A plasmid (Stratagene, La Jolla, CA). E. coli strain BL21-10R1.
codon plus-(DE3)-RIL (Stratagene) was used as the expression host.hIL-22 is a compact molecule of a single domain com-
The cells were grown in LB medium supplemented with 100 g/ml
posed of six  helices. A dimer of human IL-22 was ampicillin and 34 g/ml chloramphenicol. Expression of IL-22 was
found in the asymmetric unit of the crystal. Unlike IL- induced with 1 mM IPTG at a cell density (600 nm) of1. Cells were
collected by centrifugation 4 hr after induction. The cell pellet was10 and IFN-, which are V-shaped homodimers of two
Structure
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disrupted with a high-pressure cell homogenizer, and the IL-22 inclu- Model Building and Refinement
A solvent-flattened electron density map and structure factor ampli-sion bodies were collected by centrifugation. Inclusion bodies were
washed extensively, first with 50 mM Tris-HCl, 100 mM NaCl, 1 mM tudes from the iodine derivative were used by the ARP/wARP pro-
gram [26] for an automatic build of a hybrid model of hIL-22. DueEDTA, 1 mM DTT, and 0.5% (w/v) DOC (pH 8) and finally with the
same buffer without detergent. Inclusion bodies were solubilized to the high resolution and completeness of the I-hIL-22 data set,
an initial model was obtained without manual intervention after sixovernight at 4C in 8 M urea, 50 mM MES, 10 mM EDTA, and 0.1
mM DTT (pH 5.5). The solution was centrifuged for 1 hr at 100,000  ARP/wARP jobs and more than 4000 REFMAC [48] cycles. In the
last cycle, after almost 72 hr of uninterrupted CPU time on a Pentiumg, and the supernatant was stored at 80C until use. The purity
of the IL-22 was estimated at 80% based on SDS-PAGE and III 500 MHz, 81.6% of the total amino acid residues were correctly
traced.Coomassie blue staining analysis. The concentration of protein was
estimated by UV absorbance in urea solution using a calculated The initial model contained 231 amino acid residues (in nine dis-
tinct chains) and 809 water molecules. To avoid modeling of a large280  3840. The IL-22 protein was refolded by direct dilution of the
solubilized inclusion bodies in the following folding mixture: 100 number of partially occupied iodine ions that were present at the
concentration of 125 mM in the cryosolution of this derivative, sub-g/ml IL-22, 100 mM Tris-HCl, 2 mM EDTA, 0.5 M L-Arginine, 1 mM
reduced glutathion, and 0.1 mM oxidized glutathion (pH 8). The sequent refinement was performed against the Nat-hIL-22 data set.
Construction of disordered loops and filling of main chain gapssolution was incubated for 72 hr at 4C. The folding mixture was
then concentrated by ultrafiltration in an AMICON chamber with a were performed manually using the program O [49], and the CNS
refinement against the Nat-hIL-22 and Hg-hIL-22 (quasi-native) dataYM3 membrane before purification on a Superdex75 (Amersham
Pharmacia Biotech) gel filtration column. The protein was eluted sets was performed when judged necessary. This allowed for a
complete trace of the main chain atoms through disordered regions.with 25 mM MES and 150 mM NaCl (pH 5.4). The protein bioactivity
was assessed following procedures previously described [40]. The Independent refinement of the model against I-hIL-22 data resulted
in higher R factor and Rfree values, due to a large number of halidesrecombinant protein was found to be fully active. Human IL-22 peak
fractions were concentrated to 5 mg/ml with a YM3 AMICON mem- with partial occupancies bound to the protein found in the electron
density maps. After several iterations of energy minimization, Bbrane and desalted using a Hiprep 26/10 column (Amersham-Phar-
macia) with elution buffer containing 10 mM MES (pH 5.4). Human factor refinement, and bulk-solvent and anisotropic corrections, the
final R factor and Rfree against the Nat-hIL-22 data set were 0.188IL-22 was concentrated again to 5 mg/ml and lyophilized in 1 mg
fractions. and 0.220, respectively. The final model includes 283 residues di-
vided into two chains and 189 water molecules.
Protein Crystallization
Protein Oligomerization StatePreliminary screening of the crystallization conditions was per-
The protein oligomerization state has been assessed by gel filtrationformed using a sparse-matrix screen at 291 K (Crystal Screen I and
and dynamic light-scattering (DLS) studies. Gel filtration experi-II; Hampton Research). Small crystals were found in the conditions
ments were conducted in the conditions described in Protein Ex-18, 26, and 29 of the Crystal Screen I kit. Several attempts to enhance
pression and Purification. DLS measurements have been performedcrystal quality were performed, including pH and precipitant con-
with a DynaPro MS200 instrument (Protein Solutions) at 20C usingcentration refinement, detergent addition, and macroseeding. Well-
a 12 l cuvette. The protein samples were concentrated to 5 mg/diffracting crystals were obtained in hanging drops equilibrated
ml and 10 mg/ml in 0.1 M HEPES buffer at pH 7.5 prior to measure-against a reservoir solution consisting of 0.9 M sodium tartrate,
ments.TRITON X-100 detergent, and 0.1 M HEPES (pH 7.5). The crystalliza-
tion drops contained equal volumes (1 l) of reservoir and purified
hIL-22 (10 mg/ml in 20 mM MES buffer at pH 5.4) solutions. The Acknowledgments
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